RedHill Biopharma Ltd. (RDHL)

0,4280 +0,0093 (+2,22%) Alla chiusura: 04:00PM EDT

RedHill Biopharma Ltd.

21 Ha’arba’a Street
Tel Aviv 6473921
Israel
972 3 541 3131
https://www.redhillbio.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 53

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Dror Ben-Asher	Co-Founder, Chairman & CEO	594,61k	N/D	1966
Mr. Razi Ingber	Chief Financial Officer	339,82k	N/D	1984
Mr. Gilead Raday MPhil, MSc	Chief Operating Officer	365,56k	N/D	1975
Mr. Adi Frish	Chief Corporate & Business Development Officer	339,3k	N/D	1970
Mr. Rick D. Scruggs	Chief Commercial Officer, President of RedHill Biopharma Inc. & Director	469,8k	N/D	1960
Ms. Alexandra Okmian	Senior Business Development & Investor Relations Manager	N/D	N/D	N/D
Dr. Reza Fathi Ph.D.	Senior Vice President of Research & Development	299,29k	N/D	1955
Mr. Guy Goldberg J.D.	Chief Business Officer	338,13k	N/D	1976
Dr. June S. Almenoff FACP, M.D., Ph.D.	Chief Medical Officer	N/D	N/D	1957
Ms. Patricia Anderson B.Sc. RAC	Senior Vice President of Regulatory Affairs	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Governance aziendale

L'ISS Governance QualityScore di RedHill Biopharma Ltd. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.